CrossBridge Bio

CrossBridge Bio is a private, preclinical-stage biotech company developing next-generation Antibody-Drug Conjugates (ADCs) for oncology. Its core technology platform features two key innovations: the EGCit enzymatically cleavable linker for enhanced stability and hydrophilicity, and an enzymatic conjugation method using microbial transglutaminase (mTG) to create uniform, dual-payload ADCs with precise Drug-to-Antibody Ratios (DAR). The company aims to create first-in-class and best-in-class ADC candidates by enabling synergistic antibody-payload pairings, though it remains pre-revenue and faces significant development and competitive risks common to early-stage biotechs.

Proprietary ADC platform featuring the EGCit (GluGlyCit) enzymatically cleavable linker for enhanced stability and hydrophilicity, and a microbial Transglutaminase (mTG)-based enzymatic conjugation system for site-specific attachment of branched linkers, enabling the creation of homogeneous, dual-payload ADCs with precise Drug-to-Antibody Ratio (DAR) control.

The ADC field is highly competitive, dominated by large pharma (e.g., AstraZeneca, Pfizer, Roche) and specialized biotechs (e.g., ImmunoGen, Seagen [now Pfizer], Mersana) with advanced platforms. Competition focuses on novel linkers, payloads, conjugation methods, and bispecific formats. CrossBridge Bio must differentiate its dual-payload approach against these established and deep-pocketed players.